FindTrial
Sign In

CT-P16

DRUG2 trials

Sponsors

Celltrion

Conditions

Adenocarcinoma of LungHealthy

Phase 1

To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin
CompletedNCT03247673
CelltrionHealthy
Start: 2017-08-07End: 2018-01-17Updated: 2020-03-26

Phase 3

To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
CompletedNCT03676192
CelltrionAdenocarcinoma of Lung
Start: 2019-02-01End: 2023-09-19Updated: 2025-03-17

Related Papers

Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin<sup>®</sup> and US-Avastin<sup>®</sup> in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer.
2026-08-02
Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.
2025-07-24
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
2022-09-289 citations
Abstract CT551: Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin®) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)
Cancer Research2022-06-151 citations
A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
2019-04-0115 citations